October 24, 2024 MGH Cancer Center Grand Rounds 2024-2025: Considering Race and Ancestry When Studying Cancer Risk, Prevention, Early Detection and Treatment - Archived

Description

This activity provides on-demand archived lectures from the MGH Cancer Center Grand Rounds 2024-2025 series. As one of the leading academic cancer centers in the country, our research and clinical staff need to be educated on cutting edge information on advances and perspectives on cancer research and treatment across the full spectrum of cancer specialization. This will help clinicians understand, assess and apply this information in our rapidly advancing and highly specialized organization.  Clinicians will present and discuss this information in a multi-specialty setting. Clinicians will be informed and challenged across the organization to reach beyond their own specialization and role, and support higher levels of learning and competence for themselves, teams, and functions.

The theme of the series is "Early Detection" and kicks off Thursday September 19, 2024 at 12:00 PM EDT.  The series will cover a comprehensive array of disease areas and topics, attendees will be provided with a robust selection of sessions to bring them up to speed on the most cutting-edge research and therapies in oncology.

 

Course Director: Colin D. Weekes, MD, PhD

Coordinator: Stephanie Dimodica  (SDIMODICA@mgh.harvard.edu)

For questions regarding the registration process, please contact Mass General Brigham Office of Continuing Professional Development at mgbcpd@mgb.org.

You may print individual certificates throughout the year; your cumulative list of sessions attended is accessible on your transcript.

Target Audience

This activity is intended for Physicians, Nurses, APPs, trainees with specialties of Oncology,

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Evaluate recent advances in early detection research and programs presented in this series.
  2. Assess opportunities to integrate early detection into how you support research.
  3. Assess opportunities to integrate early detection practices & strategies into how you deliver patient care.
  4. Recognize the impact and evolving landscape of early detection in cancer care worldwide.

Additional Information

Provided by: 

Provided by Mass General Brigham

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Nursing Contact Hours
  • 1.00 Participation
Course opens: 
07/01/2024
Course expires: 
06/30/2026
Cost:
$0.00
Part of: 
MGH Cancer Center Grand Rounds 2024-2025: Archived
Massachusetts General Hospital
Boston, MA 02114
United States

Course Directors

Colin D. Weekes, MD, PhD - Course Director
Director, Medical Oncology Research for Pancreatic Cancer,
Director, Cancer Center Grand Rounds Program
Massachusetts General Hospital

Douglas Micalizzi, MD, PhD
Clinical Director, Cancer Early Detection and Diagnostics Clinic,
Massachusetts General Hospital Cancer Center

Lecia Sequist, MD, MPH
Program Director, Cancer Early Detection and Diagnostics Clinic,
Massachusetts General Hospital Cancer Center;
Landry Family Professor of Medicine
Harvard Medical School

Faculty

Congressman Jake Auchincloss,
Representing the 4th District of Massachusetts

DISCLOSURE SUMMARY OF RELEVANT FINANCIAL RELATIONSHIPS

MITIGATION STRATEGIES
Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public. 

The following planners reported no relevant financial relationship with an ineligible company:

Kellyanne Jeffries, CNP
Douglas Micalizzi, MD, PhD

The following planners have reported a relevant financial relationship with an ineligible company:

 

Colin D. Weekes, MD, PhD
Consultant: Ipsen, Genentech, Actuate Therapeutics
Research Funding: Novartis, Genentech, Actuate Therapeutics, Elicio Therapeutics, OncoC4, Deciphera Pharmaceuticals
Scientific Advisory Board: VRise Therapeutics

Lecia Sequist, MD, MPh
Institutional Research Funding: AstraZeneca, Novartis, Delfi Diagnostics

 

The following speaker reported no relevant financial relationship with an ineligible company:

Congressman Jake Auchincloss

The following speaker reported a relevant financial relationship with an ineligible company:

ACCREDITATION

In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AMA PRA Category 1 CreditTM
Mass General Brigham designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing
Mass General Brigham designates this activity for 1 ANCC contact hour. Nurses should only claim credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Nursing Contact Hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.